Published in J Clin Immunol on May 02, 2006
Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics (2010) 1.53
Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int (2008) 1.43
Aberrant Wound Healing in an Epidermal Interleukin-4 Transgenic Mouse Model of Atopic Dermatitis. PLoS One (2016) 1.41
A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One (2011) 1.34
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem (2011) 1.16
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs (2012) 1.10
Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am J Pathol (2009) 1.05
Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol (2015) 1.03
Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest (2009) 0.98
Barx2 and Fgf10 regulate ocular glands branching morphogenesis by controlling extracellular matrix remodeling. Development (2011) 0.98
Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury. Curr Opin Organ Transplant (2011) 0.97
Increased degradation of extracellular matrix structures of lacrimal glands implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol (2007) 0.97
AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon β. PLoS One (2012) 0.95
Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis. Am J Pathol (2008) 0.94
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One (2015) 0.90
Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus. Gastroenterology (2011) 0.90
Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J Virol (2008) 0.89
Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. J Autoimmun (2014) 0.88
MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonas gingivalis. FEMS Immunol Med Microbiol (2010) 0.88
Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One (2013) 0.87
Neuroendocrine immunoregulation in multiple sclerosis. Clin Dev Immunol (2013) 0.87
Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9. Br J Pharmacol (2012) 0.85
Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One (2013) 0.85
Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis. Arthritis Res Ther (2014) 0.84
Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol (2013) 0.83
Recognition of Streptococcus pneumoniae and muramyl dipeptide by NOD2 results in potent induction of MMP-9, which can be controlled by lipopolysaccharide stimulation. Infect Immun (2014) 0.83
Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J Biomed Sci (2009) 0.83
Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int (2009) 0.82
Activated protein C: A regulator of human skin epidermal keratinocyte function. World J Biol Chem (2014) 0.82
Human parvovirus B19 NS1 protein aggravates liver injury in NZB/W F1 mice. PLoS One (2013) 0.81
Effects of human parvovirus B19 VP1 unique region protein on macrophage responses. J Biomed Sci (2009) 0.80
A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One (2012) 0.80
Quercetin and sulforaphane in combination suppress the progression of melanoma through the down-regulation of matrix metalloproteinase-9. Exp Ther Med (2010) 0.79
Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression. Oncol Lett (2015) 0.79
Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J (2012) 0.79
Postnatal hyperoxia exposure differentially affects hepatocytes and liver haemopoietic cells in newborn rats. PLoS One (2014) 0.78
Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review. World J Gastroenterol (2015) 0.78
Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm (2016) 0.78
Micropatterned surfaces functionalized with electroactive peptides for detecting protease release from cells. Anal Chem (2012) 0.78
Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors. PLoS One (2012) 0.78
Oxidative damage and antioxidative therapy in systemic sclerosis. Mediators Inflamm (2014) 0.77
Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin. Nitric Oxide (2009) 0.77
Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation. Radiat Environ Biophys (2014) 0.76
In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients. Mediators Inflamm (2015) 0.76
Glycine tomentella Hayata inhibits IL-1β and IL-6 production, inhibits MMP-9 activity, and enhances RAW264.7 macrophage clearance of apoptotic cells. J Biomed Sci (2010) 0.76
Zinc in Multiple Sclerosis: A Systematic Review and Meta-Analysis. ASN Neuro (2016) 0.76
Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol (2014) 0.76
Multiple sclerosis associated with systemic sclerosis. Rheumatol Int (2006) 0.75
Plasma Levels of Matrix Metalloproteinase-9 in Children With Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res (2016) 0.75
A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat Immunol (2016) 0.75
Family Analysis of Linkage and Association of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9 and TIMP1 Gene Polymorphisms with Multiple Sclerosis. Acta Naturae (2011) 0.75
Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. J Biol Chem (2017) 0.75
Markers of inflammation and influence of nitric oxide on platelet activation in the course of ulcerative colitis. Oncotarget (2017) 0.75
Effect of Liuweibuqi capsules on the balance between MMP-9 and TIMP1 and viability of alveolar macrophages in COPD. Biosci Rep (2017) 0.75
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem (2003) 4.33
Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol (2004) 4.16
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol (2001) 2.66
Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol (2001) 2.16
Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol (2001) 1.67
Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol (1996) 1.27
Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis (2003) 1.26
Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology (1996) 1.24
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain (1998) 1.15
A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol (1998) 1.12
Clinical implications of matrix metalloproteinases. Mol Cell Biochem (2003) 1.08
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain (1998) 1.07
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler (2002) 1.04
Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain (2001) 1.02
Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol (2002) 1.02
Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun (2003) 0.99
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther (2004) 0.99
Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). J Clin Endocrinol Metab (2001) 0.95
Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med (2005) 0.95
Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology (2000) 0.93
Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol (1998) 0.93
Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum (2000) 0.91
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg (2005) 0.89
Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer (2002) 0.82
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol (2004) 0.81
The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) (2004) 0.80
Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev (2002) 0.80
Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus. Mol Pathol (2003) 0.79
Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol (2002) 0.78
Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler (2004) 0.77
In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy (2004) 0.77
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
Functional class in patients with heart failure is associated with the development of diabetes. Am J Med (2003) 2.10
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54
Gender and autoimmunity. Autoimmun Rev (2006) 1.54
Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51
Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46
Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42
The changing face of Lemierre's syndrome. Isr Med Assoc J (2003) 1.41
Endothelial dysfunction: a crystal ball prediction for enhanced cardiovascular risk? Isr Med Assoc J (2003) 1.41
Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38
Infections and SLE. Autoimmunity (2005) 1.38
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35
Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum (2010) 1.31
Infections and autoimmunity--friends or foes? Trends Immunol (2009) 1.31
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29
Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun (2012) 1.28
Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol (2011) 1.28
Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum (2007) 1.27
The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 1.27
A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol (2011) 1.27
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26
Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol (2012) 1.25
Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.25
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol (2012) 1.23
Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol (2013) 1.23
Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol (2005) 1.23
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev (2004) 1.22
Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol (2008) 1.19
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum (2007) 1.19
Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 1.19
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun (2013) 1.19
Juvenile idiopathic arthritis. Autoimmun Rev (2005) 1.18
Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol (2007) 1.18
SLE and infections. Clin Rev Allergy Immunol (2003) 1.17
The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 1.17
The infectious etiology of vasculitis. Autoimmunity (2009) 1.16
Hyperprolactinemia and autoimmune diseases. Autoimmun Rev (2006) 1.15
The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol (2007) 1.15
Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol (2013) 1.14
Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol (2003) 1.14
Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol (2009) 1.13
Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol (2007) 1.12
Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol (2002) 1.12
Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol (2012) 1.12
Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity (2004) 1.12
Post-influenza vaccination vasculitides: a possible new entity. J Clin Rheumatol (2009) 1.11
Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci (2007) 1.11
Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.11
Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum (2004) 1.11
Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology (2010) 1.10
Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma. Isr Med Assoc J (2005) 1.10
Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev (2011) 1.10
Cognitive impairment in antiphospholipid syndrome: evidence from animal models. Clin Rheumatol (2012) 1.08